CVE-2026-93531gedelumbung HospitalManagement cross-site request forgery
Updated under an hour ago ()
Does this affect you?
It affects gedelumbung HospitalManagement. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
A weakness has been identified in gedelumbung HospitalManagement up to c2d45543789a3887067d3915f69d44cfc2cf76a8. This vulnerability affects unknown code. This manipulation causes cross-site request forgery. The attack may be initiated remotely. The exploit has been made available to the public and could be used for attacks. This product uses a rolling release model to deliver continuous updates. As a result, specific version information for affected or updated releases is not available. The project was informed of the problem early through an issue report but has not responded yet.
- CVSS
- 4.3 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N/E:P/RL:X/RC:R
- Weakness (CWE)
- CWE-352, CWE-862
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- VulDB
- NVD analysis
- Deferred
- Record last updated
- Sep 18, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
gedelumbung HospitalManagement gedelumbung:hospitalmanagement | c2d45543789a3887067d3915f69d44cfc2cf76a8 | CNA record |
References
- https://vuldb.com/vuln/407444vdb-entry
- https://vuldb.com/vuln/407444/ctisignature, permissions-required
- https://vuldb.com/cve/CVE-2026-93531third-party-advisory
- https://vuldb.com/submit/943244third-party-advisory
- https://github.com/gedelumbung/HospitalManagement/issues/6exploit, issue-tracking
- https://github.com/gedelumbung/HospitalManagement/product
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.